Ryoko Takei

885 total citations
9 papers, 498 citations indexed

About

Ryoko Takei is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Ryoko Takei has authored 9 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Ryoko Takei's work include Diabetes Treatment and Management (3 papers), Metabolism, Diabetes, and Cancer (3 papers) and Mast cells and histamine (2 papers). Ryoko Takei is often cited by papers focused on Diabetes Treatment and Management (3 papers), Metabolism, Diabetes, and Cancer (3 papers) and Mast cells and histamine (2 papers). Ryoko Takei collaborates with scholars based in Japan, Netherlands and Indonesia. Ryoko Takei's co-authors include Toyoshi Inoguchi, Noriyuki Sonoda, Yasutaka Maeda, Ryoichi Takayanagi, Hisashi Yokomizo, Noriko Ikeda, Jing Zheng, Tomoaki Inoue, Masakazu Fujii and Kei Fukuda and has published in prestigious journals such as PLoS ONE, Diabetologia and American Journal of Physiology-Endocrinology and Metabolism.

In The Last Decade

Ryoko Takei

9 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryoko Takei Japan 8 201 177 134 110 109 9 498
Ida Pastore Italy 14 307 1.5× 188 1.1× 66 0.5× 181 1.6× 111 1.0× 26 743
Olga V. Fedorova United States 11 150 0.7× 229 1.3× 91 0.7× 70 0.6× 75 0.7× 22 546
Liad Hinden Israel 13 161 0.8× 138 0.8× 34 0.3× 176 1.6× 98 0.9× 25 568
Jennifer L. Pietrusz United States 8 122 0.6× 262 1.5× 54 0.4× 42 0.4× 78 0.7× 8 486
Nikolai I. Kolodkin Russia 7 145 0.7× 244 1.4× 60 0.4× 64 0.6× 57 0.5× 8 496
Liliya M. Yamaleyeva United States 18 247 1.2× 155 0.9× 139 1.0× 139 1.3× 78 0.7× 38 833
Jung-Nan Wei Taiwan 11 79 0.4× 182 1.0× 34 0.3× 55 0.5× 81 0.7× 12 432
Pablo Cabral United States 12 144 0.7× 160 0.9× 41 0.3× 42 0.4× 142 1.3× 23 435
Kanako Bokuda Japan 10 336 1.7× 288 1.6× 92 0.7× 122 1.1× 42 0.4× 31 697
Adela Brahimaj Netherlands 9 144 0.7× 116 0.7× 48 0.4× 44 0.4× 71 0.7× 9 404

Countries citing papers authored by Ryoko Takei

Since Specialization
Citations

This map shows the geographic impact of Ryoko Takei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryoko Takei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryoko Takei more than expected).

Fields of papers citing papers by Ryoko Takei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryoko Takei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryoko Takei. The network helps show where Ryoko Takei may publish in the future.

Co-authorship network of co-authors of Ryoko Takei

This figure shows the co-authorship network connecting the top 25 collaborators of Ryoko Takei. A scholar is included among the top collaborators of Ryoko Takei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryoko Takei. Ryoko Takei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Takei, Ryoko, Tomoaki Inoue, Noriyuki Sonoda, et al.. (2019). Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. PLoS ONE. 14(10). e0223302–e0223302. 56 indexed citations
2.
Suzuki, Takeo, Ryoko Takei, Toyoshi Inoguchi, et al.. (2015). Clinical significance of barriers to blood glucose control in type 2 diabetes patients with insufficient glycemic control. Patient Preference and Adherence. 9. 837–837. 10 indexed citations
3.
Yokomizo, Hisashi, Toyoshi Inoguchi, Noriyuki Sonoda, et al.. (2014). Maternal high-fat diet induces insulin resistance and deterioration of pancreatic β-cell function in adult offspring with sex differences in mice. American Journal of Physiology-Endocrinology and Metabolism. 306(10). E1163–E1175. 104 indexed citations
4.
Maeda, Yasutaka, Toyoshi Inoguchi, Ryoko Takei, et al.. (2012). Chymase inhibition prevents myocardial fibrosis through the attenuation of NOX4‐associated oxidative stress in diabetic hamsters. Journal of Diabetes Investigation. 3(4). 354–361. 22 indexed citations
5.
Inoguchi, Toyoshi, Yasutaka Maeda, Noriko Ikeda, et al.. (2012). GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism. 61(10). 1422–1434. 203 indexed citations
6.
Ikeda, Noriko, Toyoshi Inoguchi, Noriyuki Sonoda, et al.. (2011). Biliverdin protects against the deterioration of glucose tolerance in db/db mice. Diabetologia. 54(8). 2183–2191. 50 indexed citations
7.
Maeda, Yasutaka, Toyoshi Inoguchi, Ryoko Takei, et al.. (2010). Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. American Journal of Physiology-Renal Physiology. 299(6). F1328–F1338. 40 indexed citations
8.
Tajiri, Yuji, Ryoko Takei, Kazuo Mimura, & Fumio Umeda. (2008). Attenuated metabolic effect of waist measurement in Japanese female patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 82(1). 66–72. 2 indexed citations
9.
Tajiri, Yuji, Ryoko Takei, Kazuo Mimura, & Fumio Umeda. (2007). Indicators for the Efficacy of Pioglitazone Before and During Treatment in Japanese Patients with Type 2 Diabetes. Diabetes Technology & Therapeutics. 9(5). 429–437. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ida Pastore Breakdown of academic impact, for papers by Olga V. Fedorova Breakdown of academic impact, for papers by Liad Hinden Breakdown of academic impact, for papers by Jennifer L. Pietrusz Breakdown of academic impact, for papers by Nikolai I. Kolodkin Breakdown of academic impact, for papers by Liliya M. Yamaleyeva Breakdown of academic impact, for papers by Jung-Nan Wei Breakdown of academic impact, for papers by Pablo Cabral Breakdown of academic impact, for papers by Kanako Bokuda Breakdown of academic impact, for papers by Adela Brahimaj
Rankless by CCL
2026